Search results for "THROMBOSIS"

showing 10 items of 630 documents

Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes …

2015

Clinical data on the early and midterm outcomes of bioresorbable vascular scaffolds (BVS) in routine clinical practice are limited. To fill this gap, we report on the early and midterm clinical outcomes of PCI with everolimus-eluting BVS from the large multicentre GHOST-EU registry.Between November 2011 and January 2014, 1,189 patients underwent percutaneous coronary intervention with one or more BVS (Absorb BVS; Abbott Vascular, Santa Clara, CA, USA) at 10 European centres. The primary outcome of interest was target lesion failure (TLF), defined as the combination of cardiac death, target vessel myocardial infarction, or clinically driven target lesion revascularisation (TLR). A total of 1…

MaleReoperationTarget lesionmedicine.medical_specialtymedicine.medical_treatmentMyocardial InfarctionAntineoplastic AgentsComorbidityCoronary Artery DiseaseAngina PectorisPercutaneous Coronary InterventionRisk FactorsInterquartile rangeInternal medicineAbsorbable ImplantsDiabetes MellitusmedicineHumansCumulative incidenceEverolimusMyocardial infarctionAcute Coronary SyndromeAgedProportional Hazards ModelsTissue Scaffoldsbusiness.industryHazard ratioPercutaneous coronary interventionDrug-Eluting StentsThrombosisMiddle Agedmedicine.diseaseThrombosisSurgeryEuropeTreatment OutcomeCardiovascular DiseasesConventional PCICardiologyFemaleCardiology and Cardiovascular MedicinebusinessEuroIntervention
researchProduct

Use and durability of femoral vein for autologous reconstruction with infection of the aortoiliofemoral axis.

2014

Objective To analyze early and late mortality, venous morbidity, reinfection, and freedom from reintervention after using the femoral vein (FV) for vascular reconstruction with infection of the aortoiliofemoral axis. Methods By reviewing our database, 86 patients could be identified with implantation of FV grafts in infected fields between November 1995 and July 2012. The patient records were retrospectively analyzed and follow-up information obtained from patients or their general physician. Seventy-one patients presented with prosthetic graft infection and 15 with an infected aneurysm. For data analysis, patients were divided into an aortoiliac (n = 67) and a femoral group (n = 19). Study…

MaleReoperationmedicine.medical_specialtyProsthesis-Related InfectionsTime FactorsDeep veinLimb salvageFemoral veinKaplan-Meier EstimateAortographyBlood Vessel Prosthesis ImplantationAneurysmRecurrenceRisk FactorsmedicineHumansAutograftsVascular PatencyAgedRetrospective StudiesAged 80 and overVenous Thrombosisbusiness.industryIncidence (epidemiology)Operative mortalityGraft Occlusion VascularFemoral VeinMiddle AgedPlastic Surgery Proceduresmedicine.diseaseLimb SalvageThrombosisSurgeryAortic AneurysmBlood Vessel ProsthesisFemoral ArteryVenous thrombosismedicine.anatomical_structureTreatment OutcomeIliac AneurysmSurgeryFemalebusinessCardiology and Cardiovascular MedicineTomography X-Ray ComputedAneurysm InfectedJournal of vascular surgery
researchProduct

Brain-Derived Neurotrophic Factor But Not Forced Arm Use Improves Long-Term Outcome After Photothrombotic Stroke and Transiently Upregulates Binding …

2008

Background and Purpose— Both application of neurotrophic factors like brain-derived neurotrophic factor (BDNF) and constraint-induced movement therapy like forced arm use have been shown to potentially improve outcome after stroke. The aim of the present study was to check whether postischemic long-term outcome correlates to specific modifications in the abundance of various neurotransmitter receptors. Methods— Adult male Wistar rats were subjected to photothrombotic ischemia and assigned to various treatment groups (n=5 each) with end points at 3 and 6 weeks: (1) ischemic control (saline); (2) BDNF (ischemia, 20 μg BDNF); (3) forced arm use (ischemia, saline, and ipsilateral plaster cast …

MaleRestraint PhysicalMotor ActivityLigandsDownregulation and upregulationNeurotrophic factorsForelimbmedicineAnimalsRats WistarReceptorGABA Agonistsalpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic AcidStrokePhysical Therapy ModalitiesAdvanced and Specialized NursingBrain-derived neurotrophic factorMuscimolbusiness.industryBrain-Derived Neurotrophic FactorGlutamate receptorBrainCerebral Infarctionmedicine.diseaseRatsUp-RegulationStrokemedicine.anatomical_structureReceptors Glutamatenervous systemAnesthesiaExcitatory postsynaptic potentialAutoradiographyNeurology (clinical)Dizocilpine MaleateIntracranial ThrombosisForelimbCardiology and Cardiovascular MedicinebusinessExcitatory Amino Acid AntagonistsNeuroscienceStroke
researchProduct

A novel approach to define risk of stent thrombosis after percutaneous coronary intervention with drug-eluting stents: the DERIVATION score.

2009

Recent studies of drug-eluting stents (DES) use in routine clinical practice have led to concern regarding their long-term safety and to questions about the adequacy of current antiplatelet therapy guidelines. This study sought to derivate a risk score for predicting stent thrombosis after drug-eluting stenting. The large single center DES Real-world Incremental Value in the erA of percutaneous revascularizaTION (DERIVATION) database, collecting data about 1,377 patients of any age undergoing PCI with DES as treatment for symptomatic coronary artery disease, was use for this purpose. Logistic regression and bootstrap procedure were used to select correlates of stent thrombosis that were sub…

MaleRiskmedicine.medical_specialtyDatabases Factualmedicine.medical_treatmentRevascularizationCoronary AngiographyPredictive scoreCoronary artery diseaseAngioplastyInternal medicineMedicineHumansProspective StudiesAcute Coronary SyndromeAngioplasty Balloon CoronaryAgedFramingham Risk Scorebusiness.industryStent thrombosis.Percutaneous coronary interventionDrug-Eluting StentsThrombosisGeneral MedicineOdds ratioMiddle Agedmedicine.diseasePrognosisThrombosisLogistic ModelsConventional PCIMultivariate AnalysisCardiologyFemaleRadiologyDrug-eluting stentCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation InhibitorsFollow-Up StudiesForecastingClinical research in cardiology : official journal of the German Cardiac Society
researchProduct

Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy.

2010

Summary. Background: Prothrombin time (PT) and the international normalized ratio (INR) are still routinely measured in patients with liver cirrhosis to ‘assess’ their bleeding risk despite the lack of correlation with the two. Thrombin generation (TG) assays are global assays of coagulation that are showing promise in assessing bleeding and thrombosis risks. Aim: To study the relationship between the INR and TG profiles in cirrhosis-induced coagulopathy. Methods: Seventy-three patients with cirrhosis were studied. All TG parameters were compared with those from a normal control group. Contact activation was prevented using corn trypsin inhibitor. TG was also assayed in the presence of Prot…

MaleRiskmedicine.medical_specialtyPathologyCirrhosisHemorrhageGastroenterologyThrombin generationLag timeFibrinolytic AgentsInternal medicinemedicineCoagulopathyHumansIn patientInternational Normalized RatioBlood CoagulationAgedbusiness.industryThrombinAnticoagulantsHematologyBlood Coagulation DisordersMiddle Agedmedicine.diseaseThrombosisFibrosisCoagulationLiverIntercellular Signaling Peptides and ProteinsFemalebusinessPeptidesProtein Cmedicine.drugProtein CJournal of thrombosis and haemostasis : JTH
researchProduct

Dabigatran after Short Heparin Anticoagulation for Acute Intermediate-Risk Pulmonary Embolism: Rationale and Design of the Single-Arm PEITHO-2 Study

2017

AbstractPatients with intermediate-risk pulmonary embolism (PE) may, depending on the method and cut-off values used for definition, account for up to 60% of all patients with PE and have an 8% or higher risk of short-term adverse outcome. Although four non-vitamin K-dependent direct oral anticoagulants (NOACs) have been approved for the treatment of venous thromboembolism, their safety and efficacy as well as the optimal anticoagulation regimen using these drugs have not been systematically investigated in intermediate-risk PE. Moreover, it remains unknown how many patients with intermediate-high-risk and intermediate-low-risk PE were included in most of the phase III NOAC trials. The ongo…

MaleRiskmedicine.medical_specialtypulmonary embolismDrug-Related Side Effects and Adverse Reactionsmedicine.medical_treatmentHemorrhageintermediate risk030204 cardiovascular system & hematologyDabigatran03 medical and health sciencesYoung Adult0302 clinical medicineRecurrenceInternal medicineGermanymedicineHumansdabigatran030212 general & internal medicineProspective StudiesProspective cohort studySurvival analysisvenous thromboembolism recurrencebusiness.industryHeparinAnticoagulantsHematologyThrombolysisHeparinReference Standardsmedicine.diseaseThrombosisSurvival Analysis3. Good healthPulmonary embolismright ventricular functionRegimenTreatment OutcomeResearch Designmajor bleedingAcute Diseasedabigatran; intermediate risk; major bleeding; pulmonary embolism; right ventricular function; venous thromboembolism recurrenceFemalebusinessmedicine.drugFollow-Up Studies
researchProduct

Early Seizures After Acute Stroke: A Study of 1,640 Cases

1994

We evaluated prospectively the occurrence of seizures within 15 days of a first stroke or transient ischemic episode in 1,640 patients to study relation between seizures and type of stroke. Seizures occurred in 90 patients (5.4%), including 36 (4.4%) of 814 with infarct owing to atheroma, 21 (16.6%) of 126 with infarct owing to cardiogenic embolus, 3 (1%) of 273 owing to lacunar infarct, 5 (1.9%) of 259 owing to transient ischemic attack (TIA), 21 (16.2%) of 129 owing to supratentorial hematoma, and 4 (16.6%) of 24 owing to subarachnoid hemorrhage. Thirteen (14.6%) of 89 subcortical infarcts were associated with seizures. Seizures were the initial sign of stroke in 80 (89%) of 90 cases and …

MaleSubarachnoid hemorrhageComorbidityCentral nervous system diseaseHematomaEmbolusmedicineHumansProspective StudiesRegistriescardiovascular diseasesProspective cohort studyStrokeAgedAged 80 and overEpilepsybusiness.industryVascular diseaseIncidenceCerebral InfarctionIntracranial Embolism and ThrombosisMiddle AgedSubarachnoid HemorrhageIntracranial Arteriosclerosismedicine.diseaseCerebrovascular DisordersNeurologyEmbolismIschemic Attack TransientAnesthesiacardiovascular systemRegression AnalysisFemaleFranceNeurology (clinical)businessEpilepsia
researchProduct

Five-Year Results of the Bioflow-III Registry:Real-World Experience with a Biodegradable Polymer Sirolimus-Eluting Stent

2018

Abstract Purpose We aimed to assess long-term safety and performance of the Orsiro sirolimus-eluting coronary stent with biodegradable polymer in a large unselected population and in pre-specified subgroups. Methods BIOFLOW-III is a prospective, multicenter, international, observational registry with follow-up visits scheduled at 6 and 12 months, and at 3 and 5 years ( NCT01553526 ). Results 1356 patients with 1738 lesions were enrolled. Of those, 392 (28.9%) declined to participate in the study extension from 18 months to 5 years, 37 (2.7%) withdrew consent, and 89 (6.6%) were lost to follow-up. At 5-years, Kaplan-Meier estimates of target lesion failure, defined as a composite of cardiac …

MaleTarget lesionTime Factorsmedicine.medical_treatmentMyocardial InfarctionCoronary Artery Disease030204 cardiovascular system & hematology0302 clinical medicineRecurrenceRisk FactorsAbsorbable ImplantsBiodegradable polymerProspective StudiesRegistries030212 general & internal medicineMyocardial infarctionAngioplasty Balloon Coronaryeducation.field_of_studyDiabetesDrug-Eluting StentsGeneral MedicineCoronary artery stenosisMiddle AgedTreatment OutcomeDrug-eluting stentFemaleCardiology and Cardiovascular Medicinemedicine.medical_specialtyPolyestersPopulationHybrid stentProsthesis Design03 medical and health sciencesDiabetes mellitusCoronary stentmedicineHumanseducationAgedSirolimusbusiness.industryCoronary ThrombosisStentCardiovascular Agentsmedicine.diseaseConfidence intervalSurgeryCoronary OcclusionChronic DiseaseDrug-eluting stentbusiness
researchProduct

Effects of clopidogrel vs. prasugrel vs. ticagrelor on endothelial function, inflammatory parameters, and platelet function in patients with acute co…

2020

Abstract Aims In a randomized, parallel, blinded study, we investigate the impact of clopidogrel, prasugrel, or ticagrelor on peripheral endothelial function in patients undergoing stenting for an acute coronary syndrome. Methods and results The primary endpoint of the study was the change in endothelium-dependent flow-mediated dilation (FMD) following stenting. A total of 90 patients (age 62 ± 9 years, 81 males, 22 diabetics, 49 non-ST elevation myocardial infarctions) were enrolled. There were no significant differences among groups in any clinical parameter. Acutely before stenting, all three drugs improved FMD without differences between groups (P = 0.73). Stenting blunted FMD in the cl…

MaleTicagrelormedicine.medical_specialtyAcute coronary syndromeAdenosinePrasugrelmedicine.medical_treatment030204 cardiovascular system & hematology03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineInternal medicineClinical endpointHumansMedicineEndotheliumcardiovascular diseases030212 general & internal medicineAcute Coronary SyndromeAgedbusiness.industryStentMiddle Agedmedicine.diseaseClopidogrelCoronary VesselsThrombosisConfidence intervalClopidogrelTreatment OutcomePurinergic P2Y Receptor AntagonistsCardiologyFemaleCardiology and Cardiovascular MedicinebusinessPrasugrel HydrochlorideTicagrelorPlatelet Aggregation Inhibitorsmedicine.drugEuropean Heart Journal
researchProduct

Effects of combined therapy of clopidogrel and aspirin in preventing thrombus formation on mechanical heart valves in an ex vivo rabbit model.

2002

Abstract Background: The aim of our study was to investigate the efficacy of the combination of clopidogrel and aspirin in the prevention of thrombus formation on artificial heart valves in an experimental rabbit model as compared to anticoagulation with warfarin. Methods: Studies were performed after oral administration of clopidogrel and aspirin in group I (n=9) for 5 days, after 5±2 days treatment with warfarin in group II (n=9) and without medication in group III (n=9). Leaflets from Sulzer Carbomedics bileaflet valves were placed in a flow chamber. The flow chamber was filled with blood in a continuous circulation between the carotid artery and the jugular vein. Results: In group III, …

MaleTiclopidineArtificial heart valveDrug Evaluation PreclinicalIn Vitro Techniquesmedicine.disease_causeJugular veinmedicineAnimalscardiovascular diseasesHeart valveThrombusAspirinAspirinbusiness.industryWarfarinThrombosisHematologymedicine.diseaseClopidogrelThrombosisClopidogrelMicroscopy Electronmedicine.anatomical_structureAnesthesiaHeart Valve Prosthesiscardiovascular systemDrug Therapy CombinationRabbitsWarfarinbusinessmedicine.drugThrombosis research
researchProduct